ArticleFrontiers in oncology2024
Safety of immune checkpoint inhibitor rechallenge after severe immune-related adverse events: a retrospective analysis.
Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Advancing immune checkpoint inhibitor rechallenge: key insights into efficacy, safety, and personalized strategies in advanced solid tumors.Frontiers in oncology · 2026Pooled it
- Immune checkpoint inhibitor neurotoxicity: long-term outcomes with focus on 1-year neurological sequelae.Journal for immunotherapy of cancer · 2026Article
- Immune-Related Polyradiculoneuropathy Associated With Immune Checkpoint Inhibitors: A Comprehensive Case Series.Brain and behavior · 2026Article
- Key immune checkpoint inhibitor-associated toxicities: from molecular mechanisms to clinical management.Frontiers in pharmacology · 2026Review
- Critical complications in cancer patients admitted to the ICU in the era of immunotherapy: recognition, differential diagnosis, and management.Frontiers in medicine · 2026Review
- Case Report: Immunotherapy-induced myocarditis requiring pacemaker insertion in an older adult. what happens if we rechallenge?Frontiers in oncology · 2026Article
- Immunotherapy-related cardiovascular toxicity: from mechanisms to management.Frontiers in pharmacology · 2026Review
- Patterns of immune-related adverse events and treatment responses in adolescents and young adults with melanoma during initial and rechallenge immune checkpoint inhibitor therapy.Journal for immunotherapy of cancer · 2025Article
- Neurological immune-related adverse events with checkpoint inhibitor therapy: challenges for the neurologist.Journal of neurology, neurosurgery, and psychiatry · 2025Review
- Immune Checkpoint Inhibitor-Induced Central and Peripheral Neurotoxicity: Case Series and Literature Review.Cureus · 2025Article
- Immune Checkpoint Inhibitors Beyond Progression in Various Solid Tumors: A Systematic Review and Pooled Analysis.Journal of clinical medicine · 2025Review
- Rechallenge with immune-checkpoint inhibitors in patients with advanced-stage lung cancer.Nature reviews. Clinical oncology · 2025Review
- Navigating Cardiotoxicity in Immune Checkpoint Inhibitors: From Diagnosis to Long-Term Management.Journal of cardiovascular development and disease · 2025Review
- Exceptional Response in a Patient with mRCC Through Precision-Guided Treatment Involving Immunotherapy Rechallenge with Temsirolimus and Bevacizumab.Journal of immunotherapy and precision oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitors (ICIs) present clinicians with the challenge of managing immune-related adverse events (irAEs), which can range from mild to severe due to immune system activation
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.